Are you Dr. Mucke?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 37 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1001 Potrero Ave
San Francisco, CA 94110Phone+1 415-206-8492
Summary
- Dr. Lennart Mucke, MD is a board certified neurologist in San Francisco, California. He is currently licensed to practice medicine in California and Massachusetts. He is a Director of the Gladstone Institute of Neurological Disease Joseph B. Martin Distinguished Professor of Neuroscience and a Professor of Neurology at the University of California at San Francisco (UCSF).
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1985 - 1989
- Cleveland Clinic FoundationInternship, Internal Medicine, 1984 - 1985
- Freie University Berlin Faculty of MedicineClass of 1982
Certifications & Licensure
- CA State Medical License 1988 - 2026
- MA State Medical License 1988 - 2001
- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 367 citations100 Years and Counting: Prospects for Defeating Alzheimer’s DiseaseErik D. Roberson, Lennart Mucke
Science. 2006-11-03 - 327 citationsTau post-translational modifications in wild-type and human amyloid precursor protein transgenic miceMeaghan Morris, Giselle M. Knudsen, Sumihiro Maeda, Jonathan C. Trinidad, Alexandra Ioanoviciu
Nature Neuroscience. 2015-07-20 - 103 citationsCollagen VI protects neurons against Abeta toxicity.Jason S. Cheng, Dena B. Dubal, Daniel Kim, Justin Legleiter, Irene H. Cheng
Nature Neuroscience. 2009-01-04
Press Mentions
- Q&A with Neurological Disease ExpertSeptember 10th, 2024
- Discovery of How Blood Clots Damage the Brain and Body in COVID-19 Points to New TherapyAugust 28th, 2024
- Discovery of How Blood Clots Harm Brain and Body in COVID-19 Points to New TherapyAugust 28th, 2024
- Join now to see all
Grant Support
- Mouse Models With Regulatable Cell Type-Specific Expression Of Anti-Tau ShrnasNational Institute On Aging2011–2012
- Kinases Linking Abeta And TAU To Synaptic DysfunctionNational Institute Of Neurological Disorders And Stroke2011–2012
- Behavioral CoreNational Institute Of Neurological Disorders And Stroke2011–2012
- Potential Role Of Epilepsy In Alzheimer? DiseaseNational Institute On Aging2009–2012
- Phosphoproteomic Analysis Of Synaptic Proteins In Alzheimer Disease Mouse ModelsNational Center For Research Resources2010–2011
- Differences In Post-Translational Modification Of TAU In Happ VS Normal MiceNational Center For Research Resources2010–2011
- Proteinopathies Of The Aging Central Nervous SystemNational Institute On Aging2008–2011
- Mechanisms Of Ab-Induced Neuronal DeficitsNational Institute On Aging2008–2011
- Animal CoreNational Institute On Aging2008–2011
- Administrative CoreNational Institute On Aging2007–2011
- Transgenic Models To Study Alzheimer'S DiseaseNational Institute On Aging2002–2011
- Novel Therapeutic Approaches To Alzheimer'S DiseaseNational Institute Of Neurological Disorders And Stroke2009–2010
- Roles Of Amyloid Precursor Protein And Its Metabolites In Neuronal ImpairmentNational Institute Of Neurological Disorders And Stroke2007–2010
- Phosphoproteomic Analysis Of Synaptic Proteins In Alzheimer'S DiseaseNational Center For Research Resources2009
- Molecular Indicators Of Dementia Related DeficitsNational Institute On Aging2004–2008
- Mechanisms Of Amyloid Beta Peptide-Induced Neuronal DeficitsNational Institute On Aging2007
- Core--AnimalNational Institute On Aging2007
- Proteopathies Of The Aging Central NervousNational Institute On Aging2004–2007
- Proteopathies Of The Aging Central Nervous SystemNational Institute On Aging2003–2007
- Role Of APP And Its Metabolites In Synaptic DegenerationNational Institute Of Neurological Disorders And Stroke2001–2006
- A Beta Vaccination: Mechanisms And Therapautic ImpactNational Institute Of Neurological Disorders And Stroke2001–2005
- Transgenic Models To Sudy Alzheimers DiseaseNational Institute On Aging1998–2001
- Therapeutic Targets In Transgenic MiceNational Institute Of Mental Health1997–2000
- Molecular Mechanisms Of HIV-1 NeurotoxicityNational Institute Of Mental Health1996–2000
- Etiologic Factors Of Alzheimer'S Disease And Their Analysis In Transgenic ModelsNational Institute On Aging1996–1998
- Transgenic Models To Study AIDS Dementia ComplexNational Institute Of Neurological Disorders And Stroke1995–1998
- In Vivo CNS Effects Of HIV1 Coat Proteins And NefNational Institute Of Neurological Disorders And Stroke1996–1997
- Transgenic Models To Study Alzheimers DiseaseNational Institute On Aging1996
- Transgenic Models To Study AIDS Dementia ComplexNational Institute Of Neurological Disorders And Stroke1995
- In Vivo CNS Effects Of HIV-1 Coat Proteins And NefNational Institute Of Neurological Disorders And Stroke1994–1995
- Transgenic Models To Study Alzheimers DiseaseNational Institute On Aging1994
- Transgenic Models To Study Alzheimer'S DiseaseNational Institute On Aging1992–1993
Professional Memberships
- Member